Interferon-α resistance can be reversed by inhibition of IFN-α-induced COX-2 expression potentially via STAT1 activation in A549 cells

Oncology Reports

Volumn 15, Issue 6, 2006, Pages 1541-1549

  Lee, Jeeyun ^a   Jung, Hae Hyun ^a   Im, Young Hyuck ^a   Kim, Joo Hyun ^a   Park, Joon Oh ^a   Kim, Kihyun ^a   Kim, Won Seog ^a   Ahn, Jin Seok ^a   Jung, Chul Won ^a   Park, Young Suk ^a   Kang, Won Ki ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cyclooxygenase 2; Interferon ; Non small cell lung cancer

Indexed keywords

ALPHA INTERFERON; CURCUMIN; CYCLOOXYGENASE 2; DNA; MEMBRANE PROTEIN; MESSENGER RNA; PTGS2 PROTEIN, HUMAN; STAT1 PROTEIN;

ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PHOSPHORYLATION;

CARCINOMA, NON-SMALL-CELL LUNG; CURCUMIN; CYCLOOXYGENASE 2; DNA, NEOPLASM; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; HUMANS; INTERFERON-ALPHA; LUNG NEOPLASMS; MEMBRANE PROTEINS; PHOSPHORYLATION; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR;

EID: 38349038806     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.6.1541     Document Type: Article

References (34)

1. Bae JM, Won YJ, Jung KW and Park JG: Annual Report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res Treat 34: 77-83, 2002.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
3. Dy GK and Adjei AA: Novel targets for lung cancer therapy. J Clin Oncol 20: 2881-2894, 2002. (Pubitemid 34651518)
4. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclo-oxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998. (Pubitemid 28521147)
5. Bennett A, Carroll MA, Stamford IF, Whimster WF and Williams F: Prostaglandins and human lung carcinomas. Br J Cancer 46: 888-893, 1982. (Pubitemid 13177695)
6. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T: Increased expressioin of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998. (Pubitemid 28405625)
7. Hubbard WC, Alley MC, Gray GM, Green KC, McLemore TL and Boyd M: Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non small cell carcinomas of the lung as determined in established cell lines derived from human lung tumours. Cancer Res 49: 826-832, 1989. (Pubitemid 19064330)
8. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y and Ochiai A: Increased cyclo-oxygenase 2(COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30: 73-81, 2000.
9. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2- dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998. (Pubitemid 28183210)
10. Chun KS and Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharm 68: 1089-1100, 2004.
11. Riedel K, Krysan K, Pold M, Dalwadi H, Heuze-Vourch N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S and Dubinett SM: Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Update 7: 169-184, 2004. (Pubitemid 39024518)
12. Rane SG and Reddy EP: Janus kinases: components of multiple signaling pathways. Oncogene 19: 5662-5679, 2000.
13. Schindler C, Shuai K, Prezioso VR and Darnell JE Jr: Interferondependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257: 809-813, 1992.
14. Fu XY: A transcription factor with SH2 and SH3 domains is directly activated by an interferon alpha-induced cytoplasmic protein tyrosine kinase(s). Cell 70: 323-335, 1992.
15. Kovarik P, Mangold M, Mamsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Muller M and Decker T: Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 20: 91-100, 2001. (Pubitemid 32099105)
16. Calo V, Migliavaccaw M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A: STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol 19: 157-168, 2003. (Pubitemid 37485244)
17. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B and Bolli R: Mechanism of cyclooxygenase-2 upregulation in late precondition. J Mol Cell Cardiol 35: 525-537, 2003. (Pubitemid 36539458)
18. Horvath CM, Wen Z and Darnell JE: A Stat protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 9: 984-994, 1995.
19. Decker T, Kovarik P and Meinke A: GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 17: 121-134, 1997. (Pubitemid 27148701)
20. Yamaoka K, Otsuka T, Niiro H, Arinobu Y, Niho Y, Hamasaki N and Izuhara K: Activation of STAT5 by lipopolysaccharide through granulocyte-macrophage colony-stimulating factor production in human monocytes. J Immunol 160: 838-845, 1998. (Pubitemid 28049325)
21. Lee J, Im YH, Jung HH, Kim JH, Park JO, Kim K, Kim WS, Ahn JS, Jung CW, Park YS, Kang WK and Park K: Curcumin inhibits interferon-a induced NF-κB and COX-2 in human A549 non-small cell lung cancer cells. Biochem Biophys Res Commun 334: 313-318, 2005. (Pubitemid 40982371)
22. Supino R: MTT assays. In: Methods in Molecular Biology: In vitro Toxicity Testing Protocols. vol. 43. O'Hare SM and Atterwill CK (eds). Humana Press, Totowa, pp137-149, 1998.
23. Kim HY, Park EJ, Joe E and Jou I: Curcumin suppresses Janus Kinase-STAT1 inflammatory signaling through activation of Src Homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 171: 6072-6079, 2003. (Pubitemid 37467228)
24. Eberhardt W, Kunz D, Hummel R and Pfeilschifter J: Molecular cloning of the rat inducible nitric oxides synthase gene promoter. Biochem Biophys Res Commun 223: 752-756, 1996. (Pubitemid 26246146)
25. Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Viscomi C, Masciari S, Tassone P, Abbruzzese A and Venuta S: New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 54: 1-10, 2005. (Pubitemid 40064480)
26. Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, Tassone P and Venuta S: EGF activates an inducible survival response via the Ras→ERK-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 10: 218-229, 2003. (Pubitemid 36553464)
27. Yang CH, Murti A and Lawrence MP: STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci USA 95: 5568-5572, 1998. (Pubitemid 28224135)
28. You M, Yu DH and Feng GS: Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19: 2416-2424, 1999. (Pubitemid 29098299)
29. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB and Pfeffer LM: Interferon promotes cell survival by activating nuclear factor β/α through phosphatidylinositol 3-kinase and Akt. J Biol Chem 276: 13756-13761, 2001.
30. Bostrom PJ, Uotila P, Rajala P, Nurmi M, Huhtaniemi I and Laato M: Interferon-α inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol Res 29: 20-24, 2001. (Pubitemid 32216723)
31. Thun MJ, Henley SJ and Patrono C: Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002. (Pubitemid 34196319)
32. Hung WC, Chang HC, Pan MR, Lee TH and Chuang LY: Induction of p27 (KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol 58: 1398-1403, 2000.
33. Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, Lee SH and Hong SI: Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV204) cells by up-regulating cyclindependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol 21: 379-383, 2002.
34. Shishodia S, Amin HM, Lai R and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70: 700-713, 2005. (Pubitemid 41058705)